Aurinia (Formerly Known as Isotechnika Pharma Inc.)
5120 - 75th Street
Edmonton
Alberta
T6E 6W2
Canada
Tel: 780-487-1600
Fax: 780-484-4105
Website: http://www.auriniapharma.com/
287 articles about Aurinia (Formerly Known as Isotechnika Pharma Inc.)
-
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
5/26/2020
NDA Application supported by extensive global clinical program including the pivotal Phase 3 AURORA study and the pivotal Phase 2 AURA LV study
-
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
5/14/2020
Aurinia Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational highlights.
-
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
5/7/2020
Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close.
-
Aurinia Appoints Joe Miller as Chief Financial Officer
4/27/2020
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the appointment of Joe Miller as Chief Financial Officer.
-
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
4/20/2020
Aurinia Pharmaceuticals Inc. announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Therapeutics plc, to the Company’s Board of Directors.
-
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings
3/18/2020
Data to be shared as a late-breaking oral presentation during the live virtual NKF conference
-
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
3/17/2020
Aurinia Pharmaceuticals Inc. announced that the Company has established its U.S. commercial center of operations in Rockville, Maryland.
-
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
3/16/2020
Company remains on track to complete submission by the end of the second quarter 2020 -
-
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
3/12/2020
Company recognizes World Kidney Day and National Kidney Month - Aurinia Pharmaceuticals Inc.
-
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
3/5/2020
Cash and cash equivalents totaled approximately $306 million at December 31, 2019
-
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
3/3/2020
Aurinia Pharmaceuticals Inc. announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the markets close.
-
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/21/2020
Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.
-
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
12/12/2019
The gross offering proceeds to the Company from this Offering are approximately US$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Aurinia Prices US$166.7 Million Public Offering of Common Shares
12/10/2019
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 11,115,165 common shares.
-
Aurinia Announces Public Offering of Common Shares - Dec. 9, 2019
12/9/2019
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced that it has commenced a registered underwritten public offering of US$150,000,000 of its common shares.
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
Monumental Treatment Breakthrough for Lupus Kidney Disease
12/4/2019
Trial of Voclosporin Meets All Primary and Secondary Endpoints with Clean Safety Profile
-
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
11/14/2019
Conference call and webcast to be hosted today at 4:30pm EDT
-
Aurinia Announces Updates to the Board of Directors
11/13/2019
Aurinia Pharmaceuticals Inc. announced the appointment of Ms. Jill Leversage to its Board of Directors and the resignation of Dr. Hyeuk Joon Lee.
-
Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility
10/16/2019
AURORA Phase 3 results with voclosporin for the treatment of lupus nephritis remain on track to be reported by the end of the fourth quarter 2019